BTA-EG4 hydrate can be used to diagnose, prevent or reduce the symptoms of amyloid-related diseases like Alzheimer's disease and can be used to improve cognitive function.

BTA-EG4 (40–60 μM ; 48 h) significantly reduced tau phosphorylation in the absence of any changes in the amounts of amyloid precursor protein, amyloid-β or synaptic proteins.[1]

BTA-EG4 (30 mg/kg ; injections ; daily ; 2 weeks) improved dendritic spine density and cognitive function of 3xTg AD mice in an age-dependent manner. BTA-EG4 injected 3xTg AD mice at 6-10 months of age showed improved learning and memory ; however, only minimal improvement was observed at 13-16 months of age. This behavioral improvement corresponds to a decrease in soluble Aβ 40 levels. These findings suggest that BTA-EG4 may be beneficial in ameliorating the synaptic loss seen in early AD.[2]